日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry

使用奥拉帕尼和他拉唑帕尼抑制PARP活性治疗HER2阴性晚期乳腺癌——来自前瞻性PRAEGNANT注册研究的结果

Hörner, Manuel; Hartkopf, Andreas; John, Nelson; Ziegler, Philipp; Häberle, Lothar; Uhrig, Sabrina; Goossens, Chloë; Amann, Niklas; Cieslik, Jan-Philipp; Tretschock, Lara M; Dannehl, Dominik; Deutsch, Thomas M; Dimpfl, Moritz; Ehlert, Max; Eichstädt, Kathleen; Englisch, Alexander; Köpke, Melitta B; Krückel, Annika; Link, Theresa; Müller, Annika; Reinhardt, Kristin; Roth, Jonas; Schäffler, Henning; Sych, Lea; Tauber, Nikolas; Tegeler, Christian M; Wichmann, Catharina; Banys-Paluchowski, Maggie; Princk, Henriette; Rody, Achim; Brucker, Sara Y; Ditsch, Nina; Ettl, Johannes; Fehm, Tanja; Hack, Carolin C; Hadji, Peyman; Hein, Alexander; Janni, Wolfgang W; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Taran, Florin-Andrei; Tesch, Hans; Wallwiener, Diethelm; Marmé, Frederik; Seitz, Stephan; Belleville, Erik; Michel, Laura L; Wallwiener, Markus; Fasching, Peter A; Schneeweiss, Andreas; Maurer, Christian

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial

在德国PRAEGNANT试验中,Alpelisib和Fulvestrant被用于治疗PIK3CA突变、激素受体阳性、HER2阴性的晚期乳腺癌。

Hörner, Manuel; Tretschock, Lara M; John, Nelson; Ziegler, Philipp; Häberle, Lothar; Uhrig, Sabrina; Goossens, Chloë; Amann, Niklas; Cieslik, Jan-Philipp; Dannehl, Dominik; Deutsch, Thomas M; Dimpfl, Moritz; Ehlert, Max; Eichstädt, Kathleen; Englisch, Alexander; Köpke, Melitta B; Krückel, Annika; Link, Theresa; Müller, Annika; Reinhardt, Kristin; Roth, Jonas; Schäffler, Henning; Sych, Lea; Tegeler, Christian M; Wichmann, Catharina; Banys-Paluchowski, Maggie; Princk, Henriette; Rody, Achim; Brucker, Sara Y; Ditsch, Nina; Ettl, Johannes; Fehm, Tanja; Hack, Carolin C; Hadji, Peyman; Hein, Alexander; Janni, Wolfgang W; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Schneeweiss, Andreas; Taran, Florin-Andrei; Tesch, Hans; Wallwiener, Diethelm; Marmé, Frederik; Seitz, Stephan; Belleville, Erik; Hartkopf, Andreas; Michel, Laura L; Wallwiener, Markus; Fasching, Peter A; Tauber, Nikolas

The adverse prognostic impact of reduced chemotherapy dose intensity appears attenuated in early breast cancer patients with treatment-relevant neutropenia: a retrospective cohort study

一项回顾性队列研究表明,降低化疗剂量强度对早期乳腺癌伴治疗相关性中性粒细胞减少症患者的不良预后影响似乎有所减弱。

Eissler, K; Engler, T; Dannehl, D; Schönfisch, B; Englisch, J; Hartkopf, A D; Brucker, S Y; Grischke, E M; Volmer, L L; Englisch, Alexander

Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface area

化疗剂量上限对体表面积较大的早期乳腺癌患者的治疗强度和生存率的影响

Englisch, A; Eissler, K; Dannehl, D; Englisch, J; Hartkopf, A D; Brucker, S Y; Grischke, E M; Volmer, L L; Engler, T

Quality of life after breast (reconstructive) surgery-an interim analysis of a prospective three-arm clinical trial with a 10-year follow-up (REKO 001)

乳房(重建)手术后的生活质量——一项为期 10 年的前瞻性三臂临床试验的中期分析 (REKO 001)

Boeer, B; Kandzi, J; Schoenfisch, B; Marx, M; Guergan, S; Gruber, I; Roehm, C; Helms, G; Hartkopf, A; Brucker, S Y; Hahn, M

The Pharmacy Society of Wisconsin Workforce Summit: A statewide, multidisciplinary approach to create a pharmacy workforce strategic roadmap

威斯康星州药剂师协会劳动力峰会:制定全州范围内的多学科方法,构建药剂师劳动力战略路线图

Bakken, Brianne K; Hartkopf, Katherine; Schaafsma, Kate; Hager, David

High Adherence to Adjuvant Endocrine Therapy Improves Outcome in Early Breast Cancer - Results from a Large Real-World Claims Data Analysis in Germany

德国一项大型真实世界索赔数据分析表明,早期乳腺癌患者对辅助内分泌治疗的高依从性可改善预后。

Dannehl, Dominik; Dijkstra, Tjeerd; Volmer, Lea; Hahn, Markus; von Au, Alexandra; Hawighorst-Knapstein, Sabine; Chaudhuri, Ariane; Wallwiener, Markus; Bauer, Armin; Wallwiener, Diethelm; Brucker, Sara; Wallwiener, Stephanie; Engler, Tobias; Hartkopf, Andreas

Time Toxicity of Endocrine-based Oral CDK4/6 Inhibitor Therapies

内分泌靶向口服 CDK4/6 抑制剂疗法的时间毒性

Schäffler, Henning; Heublein, Sabine; Lichtblau, Julia; Wisniewski, Lisa; Rack, Brigitte; Janni, Wolfgang; Englisch, Alexander; Englisch, Johannes; Engler, Tobias; Hartkopf, Andreas; Brucker, Sara; Hilmer, Lisbeth; Fick, Franziska; Kohls, Fabian; Banys-Paluchowski, Maggie; Rody, Achim; Dannehl, Dominik; Tauber, Nikolas

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay

利用仅血浆循环肿瘤DNA检测方法检测乳腺癌微小残留病灶并预测复发

Janni, W; Rack, B; Friedl, T W P; Hartkopf, A D; Wiesmüller, L; Pfister, K; Mergel, F; Fink, A; Braun, T; Mehmeti, F; Uhl, N; De Gregorio, A; Huober, J; Fehm, T; Müller, V; Rich, T A; Dustin, D J; Zhang, S; Huesmann, S T

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)

HR阳性HER2阴性早期乳腺癌的内分泌反应评估:WSG ADAPTcycle试验中局部与中心Ki67测量的一致性(n = 5292)

Hamann, M; Christgen, M; Gluz, O; Nitz, U; Kuemmel, S; Braun, M; Thill, M; Wuerstlein, R; Wimberger, P; Hartkopf, A; Schem, C; Zaiss, M; Bjelic-Radisic, V; Just, M; Veselinovic, K; Vincent, M; Graeser, M; Krauss, K; Hoffmann, O; Lüdtke-Heckenkamp, K; Kates, R E; Zu Eulenburg, C; Jóźwiak, K; Burmeister, S; Hauptmann, M; Baehner, F; Schmid, P; Kreipe, H-H; Harbeck, N